Adawi Kamal has filed 8 insider transactions across 2 companies since February 2024.
Most recent transaction: a grant/award of 25000 shares of FATE THERAPEUTICS INC ($FATE) on January 15, 2026.
Activity breakdown: 0 open-market purchases and 3 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 15, 2026 | FATE THERAPEUTICS INC | $FATE | Adawi Kamal | Chief Financial Officer | A | Common Stock | 25000 | $0.00 | 100,000.0000 | 118,998,693 | 33.33% | 0.02% |
| Jan. 15, 2026 | FATE THERAPEUTICS INC | $FATE | Adawi Kamal | Chief Financial Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 118,998,693 | 9999.99% | 0.06% |
| Oct. 20, 2025 | FATE THERAPEUTICS INC | $FATE | Adawi Kamal | Chief Financial Officer | A | Common Stock | 75000 | $0.00 | 75,000.0000 | 118,998,693 | 9999.99% | 0.06% |
| Oct. 20, 2025 | FATE THERAPEUTICS INC | $FATE | Adawi Kamal | Chief Financial Officer | A | Stock Option (Right to Buy) | 375000 | $0.00 | 375,000.0000 | 118,998,693 | 9999.99% | 0.32% |
| March 4, 2024 | EXAGEN INC. | $XGN | Adawi Kamal | CFO and Corporate Secretary | S | Common Stock | 9297 | $1.91 | 247,236.0000 | 17,679,467 | 3.62% | 0.05% |
| March 4, 2024 | EXAGEN INC. | $XGN | Adawi Kamal | CFO and Corporate Secretary | S | Common Stock | 3487 | $1.91 | 243,749.0000 | 17,679,467 | 1.41% | 0.02% |
| Feb. 20, 2024 | EXAGEN INC. | $XGN | Adawi Kamal | CFO and Corporate Secretary | A | Common Stock | 75000 | $0.00 | 256,533.0000 | 17,679,467 | 41.31% | 0.42% |
| Feb. 6, 2024 | EXAGEN INC. | $XGN | Adawi Kamal | CFO and Corporate Secretary | S | Common Stock | 6738 | $1.95 | 181,533.0000 | 17,679,467 | 3.58% | 0.04% |